Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen.
Ferraldeschi
Roberta
R
Howell
Sacha J
SJ
Thompson
Alastair M
AM
Newman
William G
WG
D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D009364:Neoplasm Recurrence, Local; D018570:Risk Assessment; D012307:Risk Factors; D013629:Tamoxifen / Q000378:metabolism / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6